Posard Matthew L.
SEC-identified person · CIK 1543792 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Nautilus Biotechnology, Inc. [NAUT] | Director | filed 2021 - 2026 |
| Halozyme Therapeutics, INC. Halo | Director | filed 2013 - 2026 |
| Talis Biomedical Corp TLIS | Director | filed 2021 - 2023 |
| Dermtech, Inc. DMTK | Director | filed 2019 - 2023 |
| Xenomics INC XNOM.PK | Chief Commercial Officer | filed 2015 - 2016 |
| Illumina, INC. ilmn#456 | Sr VP & General Manager | filed 2012 - 2013 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.